1. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF;Vernet Machado Bressan Wilke M;Int J Mol Sci,2024
2. Pastores GM, Hughes DA. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Amemiya A, editors. Gaucher Disease. Seattle, DC, USA: GeneReviews®. University of Washington; 1993. [(accessed on 17 September 2022)]. http://www.ncbi.nlm.nih.gov/books/NBK1269/.
3. Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review;Castillon G;J Clin Med,2022
4. Gaucher: A Systematic Review on Oral and Radiological Aspects;Minervini G;Med (Kaunas),2023
5. ADRES. Análisis De Los Recobros Correspondientes A Los Principios Activos Imiglucerasa, Miglustato, Velaglucerasa Y, Taliglucerasa Medicamentos Para La Enfermedad De Gaucher. 2017. [Internet]. [Consultado:13 de marzo 2019]. Disponible en: https://www.adres.gov.co/La-Entidad/Publicaciones/Post/5993/An%C3%A1lisis-de-los-recobros-correspondientes-a-los-principios-activos-Imiglucerasa-Miglustato-Velaglucerasa-y-Taliglucerasa-medicamentos-para-la-enfermedad-de-Gaucher.